Optimi Health Advances Psilocybin Mushroom Research

Optimi Health Corp. (TSE:OPTI) has released an update.

Optimi Health Corp. has partnered with Kwantlen Polytechnic University’s Applied Genomics Centre to conduct groundbreaking research on psilocybin mushrooms, aiming to unlock detailed genetic information that could revolutionize mushroom science. Leveraging their vast genetic bank, the collaboration focuses on DNA extraction, species identification, and strain-level identification, which could significantly improve batch consistency for medical psilocybin production.

For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.